Phase II trial of irofulven in patients with metastatic, docetaxel-resistant and castration-resistant prostate cancer.

Trial Profile

Phase II trial of irofulven in patients with metastatic, docetaxel-resistant and castration-resistant prostate cancer.

Planning
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Irofulven (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Aug 2017 According to Oncology Venture media release, company expects to commence the trial in Denmark and Sweden for >70 patients with Prostate cancer which has been screened.
    • 31 Jan 2017 According to Oncology Venture media release, earlier treatment of first patient was expected in January 2017 now Clinical Trial Application is expected filed in Q2 2017.
    • 10 Nov 2015 According to a Medical Prognosis Institute media release, a poster announcing the use of DRP (Tm) technology for this trial was published at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top